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Abstract
Background: Suppurative parotitis caused by Burkholderia pseudomallei has been rarely found outside endemic areas.
Case presentation: Herein, we report the recovery of Burkholderia pseudomallei from the pus of a suppurative parotitis
observed in a 12-year-old boy who lived in Hainan province, China. Specimens of necrotic tissue were collected and
sections were stained with hematoxylin and eosin. Pus sample was also collected for bacteriological examination.
The suppurative inflammation was observed in the necrotic tissue section and Burkholderia pseudomallei were
detected in the sample.
Conclusion: In this adolescent, Burkholderia pseudomallei infection was present in the parotid, which consists of the
first report of this bacterium in a parotitis case acquired in China.
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Background
Melioidosis, the disease caused by the bacterium Bur-
kholderia pseudomallei, is endemic to Southeast Asia
and northern Australia, and parts of South and Central
America. Infection with B. pseudomallei can be contracted
via several routes, including subcutaneous inoculation, in-
gestion, and likely inhalation [1]. Melioidosis is known as a
‘great mimicker’ since it may mimic several diseases from
pyogenic bacterial infection to tuberculosis, and there is
no pathognomonic sign of melioidosis [2–4]. The disease
has an acute and a subacute forms and also a chronic re-
lapsing state with associated high mortality. Risk factors
for infection include diabetes, alcoholism, renal insuffi-
ciency and chronic steroid use [5]. Although melioidosis
involves most organs, parotid involvement is rare. To the
best of our knowledge, confirmed melioidosis parotitis was
not previously reported except for a case that occurred
after systemic melioidosis [6]. Therefore, we describe in
this report the clinical presentation, management, and
outcome of a child with primary melioidosis parotitis.
Case presentation
The patient was a 12-year-old boy who lived in Dongfang
county, Hainan province, a region located in the tropical
area of China, who had never traveled abroad. He re-
ported occasionally swimming in the lake of his home-
town and had last did it roughly 1 month before the
illness onset. This patient presented to the medical de-
partment with severe left parotid pain and a 4.0 ×
3.5 cm swelling on the left face suggestive of parotitis.
The swelling was soft and fluctuant and it was associ-
ated with tenderness, warmth and redness. There was
no primary focus of infection found in the adjacent
draining area. He had no related symptoms of fever,
cough, expectoration or weight loss. The patient had no
history of diabetes, renal disease, chronic lung disease
or excessive alcohol consumption. He had normal vital
signs. After parotid aspiration, he immediately received
2 g of ceftazidime intravenously twice a day together
with 80 mg of gentamicin three times a day.
The investigation performed at our hospital revealed
white blood cell count of 8.1 × 109/L (69 % neutrophils),
red blood cell count of 3.94 × 1012/L, platelet count of
231 × 109/L, hematocrit of 34 %, hemoglobin concentration
of 106 g/L, glucose concentration of 6.01 mmol/L, C-
reactive protein concentration of 6.3 mg/L, and erythrocyte
sedimentation rate was elevated (92 mmHg/1st hour).
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For histologic analysis, specimens of necrotic tissue
taken during the drainage operation were fixed in 4 %
paraformaldehyde, sections were stained with hematoxylin
and eosin, and suppurative inflammation was observed
(Fig. 1). Pus was aspirated from the abscess for bacterio-
logical examination. Subsequently, samples were inocu-
lated on 5 % sheep blood agar and incubated at 37 °C in
air. After 48 h, concentric rounded shaped and creamy
white colonies were observed on the blood agar (Fig. 2).
The isolate proved to be a non-fermenting gram-negative
bacillus that was submitted to further identification using
the VITEK-2 identification system (BioMérieux, France).
VITEK-2 suggested that the isolate was Burkholderia
pseudomallei, with an excellent level of identification
(>99 %), which was confirmed by 16S rRNA gene sequen-
cing. The 16S rRNA gene was amplified by PCR using the
primers 27F (5-AGAGTTTGATCCTGGCTCAG-3) and
1525R (5-AAGGAGGTGATCCAGCC-3) [7]. Sequence
similarity searches were performed using the BLAST algo-
rithm implemented in the NCBI database.
Antibiotic susceptibility testing was performed by
broth macrodilution methods. The isolate was suscep-
tible to imipenem (MIC 2 μg/mL) and trimethoprim-
sulfamethoxazole (TMP-SMZ) (MIC 2 μg/mL). It was
resistant to the following antibiotics: ampicillin (MIC ≥
32 μg/mL), amikacin (MIC ≥ 32 μg/mL), ceftriaxone
(MIC ≥ 32 μg/mL), cefazolin (MIC ≥ 32 μg/mL), nitrofur-
antoin (MIC ≥ 32 μg/mL), gentamicin (MIC ≥ 32 μg/mL),
cefepime (MIC ≥ 32 μg/mL), levofloxacin (MIC ≥ 32
μg/mL), ceftazidime (MIC ≥ 32 μg/mL), ciprofloxacin
(MIC ≥ 32 μg/mL) and piperacillin/tazobactam (MIC ≥
32 μg/mL). According to the laboratory data, the therapy
was therefore changed to intravenous imipenem and oral
TMP-SMZ for 4 weeks. The patient was discharged with
an additional treatment of 12 weeks of oral TMP-SMZ.
Conclusions
Although data are lacking with regard to the exact loca-
tions, eight human cases of melioidosis were registered
around Hainan province [8]. In this study, we have de-
scribed a case of B. pseudomallei suppurative parotitis
in China. Our patient was from Dongfang district,
which is situated in the tropical zone of China. This
was essentially a locally acquired case, as this patient
had never travelled to any other country. To our know-
ledge, this is the first description of B. pseudomallei in
a parotitis patient acquired in China.
Best clinical judgment and focused microbiological in-
vestigations are very important for early diagnosis [9, 10].
In this case, cultures from pus grew B. pseudomallei and
the blood cultures were negative. The clinicians should
provide an early appropriate antibiotic treatment to re-
duce the risk of death caused by melioidosis. However,
therapeutic options for the treatment of melioidosis are
limited as B. pseudomallei is resistant to numerous an-
tibiotics, including aminoglycoside, penicillin, narrow-
and expanded-spectrum cephalosporin and macrolide.
B. pseudomallei is generally susceptible to TMP-SMZ,
broad-spectrum cephalosporin and carbapenem [11].
High-dose intravenous ceftazidime is currently the first
antibiotic of choice for the recommended treatment of
acute melioidosis [12]. In this case, the isolate was
Fig. 1 Histopathologic evaluation of parotid tissue specimens from the patient. Suppurative inflammation is observed in the parotid (a, b, c and d).
Hematoxylin and eosin stain, original magnification: (a) 20×, (b) 100×, (c) 200× and (d) 400×. Scale bars indicate (a) 200 μm, (b) 50 μm, or (c and d) 20 μm
Fu et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2016) 22:31 Page 2 of 3
resistant to ceftazidime and most other antibiotics. It was
only susceptible to imipenem and TMP-SMZ. Our patient
recovered following treatment with intravenous imipenem
and oral TMP-SMZ for 4 weeks, and 3 months of oral
TMP-SMZ, as per the recommendations. He was doing
well on follow-up. Intravenous imipenem and oral
TMP-SMZ may prove efficacious for the treatment of
suppurative parotitis caused by B. pseudomallei.
The presence of melioidosis may lead to several of
deaths since most laboratories of Hainan have no experi-
ence in recognizing this organism. The cases are common
enough that China is listed as one of the endemic coun-
tries for melioidosis. A high index of suspicion is needed
to diagnose these complications, even in endemic regions
like ours, as these complications can be life threatening,
and melioidosis is not commonly identified as the source
of severe presentations. Based on the present report, we
believe that infections caused by B. pseudomallei should
be included in the differential diagnosis of suppurative
parotitis in Hainan, China.
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Fig. 2 Burkholderia pseudomallei colonies on blood agar: they are
creamy white with concentric ring-like pattern
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